These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3007307)

  • 21. Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
    Wiela-Hojenska A; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Kotlarek-Haus S; Hurkacz M
    Int J Clin Pharmacol Ther; 1999 May; 37(5):234-7. PubMed ID: 10363621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of fenfluramine on disposition and rate of antipyrine elimination.
    O'Malley K; Stevenson IH; West M
    Pharmacology; 1975; 13(1):12-9. PubMed ID: 1153500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenazone metabolism in patients with liver disease.
    Andreasen PB; Greisen G
    Eur J Clin Invest; 1976 Jan; 6(1):21-6. PubMed ID: 1253807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic microsomal drug metabolism, glutamyl transferase activity and in vivo antipyrine half-life in rats chronically fed an ethanol diet, a control diet and a chow diet.
    Gadeholt G; Aarbakke J; Dybing E; Sjöblom M; Mørland J
    J Pharmacol Exp Ther; 1980 Apr; 213(1):196-203. PubMed ID: 6102148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of diethyldithiocarbamate on the metabolic elimination of hexobarbital, phenazone, tolbutamide and four halogenated hydrocarbons.
    Siegers CP; Biltz H; Pentz R
    Eur J Drug Metab Pharmacokinet; 1981; 6(2):141-8. PubMed ID: 6268415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of total parenteral nutrition on hepatic drug oxidation.
    Burgess P; Hall RI; Bateman DN; Johnston ID
    JPEN J Parenter Enteral Nutr; 1987; 11(6):540-3. PubMed ID: 3123723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver failure and drug metabolism.
    Andreasen PB; Ranek L
    Scand J Gastroenterol; 1975; 10(3):293-7. PubMed ID: 1138332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of hypoxia and pregnancy on antipyrine metabolism in isolated perfused rat livers.
    Brouwer KL; Vore M
    J Pharmacol Exp Ther; 1985 Sep; 234(3):584-9. PubMed ID: 4032283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complex, dynamically interacting host factors that affect the disposition of drugs and carcinogens.
    Vesell ES
    IARC Sci Publ; 1982; (39):427-37. PubMed ID: 6295936
    [No Abstract]   [Full Text] [Related]  

  • 30. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
    Forrest JA; Finlayson ND; Adjepon-Yamoah KK; Prescott LF
    Br Med J; 1977 May; 1(6073):1384-7. PubMed ID: 861646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impairment of drug metabolism in patients with liver cancer.
    Sotaniemi EA; Pelkonen RO; Mokka RE; Huttunen R; Viljakainen E
    Eur J Clin Invest; 1977 Aug; 7(4):269-74. PubMed ID: 196861
    [No Abstract]   [Full Text] [Related]  

  • 32. Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.
    Pelkonen O; Sotaniemi E; Tokola O; Ahokas JT
    Drug Metab Dispos; 1980; 8(4):218-22. PubMed ID: 6105054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a non-steroid anti-inflammatory agent on the drug metabolizing activity of the human liver.
    Gachályi B; Vas A; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1984 Jul; 22(7):353-4. PubMed ID: 6469424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
    Janus K; Baranow-Baranowski S; Jakubowska D
    Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of age on antipyrine metabolism in patients with gastric cancer.
    Higuchi T; Nakamura T; Uchino H
    J Natl Cancer Inst; 1980 Nov; 65(5):897-900. PubMed ID: 6933259
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J; Alsar Ortiz MJ
    Rev Clin Esp; 1993 Jun; 193(2):60-3. PubMed ID: 8341815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolism of phenazone in man after hydrocortisone administration.
    Elfström J; Lindgren S
    Eur J Clin Pharmacol; 1978 Mar; 13(1):69-72. PubMed ID: 639836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of aryl hydrocarbon hydroxylase activity of human lymphocyte cultures and plasma elimination rates for antipyrine and phenylbutazone.
    Kellermann G; Luyten-Kellermann M; Horning M; Stafford M
    Drug Metab Dispos; 1975; 3(1):47-50. PubMed ID: 234834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of physical exercise on one-sample antipyrine clearance.
    Fabbri A; Bianchi G; Zoli M; Marchi E; Marchesini G
    Ital J Gastroenterol; 1991 Feb; 23(2):74-6. PubMed ID: 1747507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antipyrine elimination as a dynamic test of hepatic functional integrity in obstructive jaundice.
    McPherson GA; Benjamin IS; Boobis AR; Brodie MJ; Hampden C; Blumgart LH
    Gut; 1982 Sep; 23(9):734-8. PubMed ID: 7106619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.